Skip to content
DraconiticResearch
Search Sources API
201,642 studies31 sourcesUpdated 17 min ago
Peer-reviewedCC BY-NC-ND 4.0In Vivo

Real-world Impact of the 21-Gene Recurrence Score on Adjuvant Treatment Decisions in Early Breast Cancer

  • NOBUYOSHI KITTAKA1
  • NAMIKO TANAKA1
  • CHISATO TAKEUCHI1
  • KANA ANNO1
  1. 1Department of Breast Surgery, Osaka Rosai Hospital, Osaka, Japan
Read full textPDFDOICite

Abstract

Background/Aim: The 21-gene recurrence score (RS) assay guides adjuvant chemotherapy decisions in hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer. We evaluated how RS results altered treatment recommendations and were integrated with clinicopathological factors in routine practice.

Patients and Methods: We retrospectively analyzed 41 consecutive patients who underwent RS testing for postoperative treatment planning at a single institution. Pre-test and post-test treatment recommendations were compared. Exploratory analyses examined patients with RS ≤25 who received chemotherapy and treatment patterns in node-positive disease.

Results: Median age was 58 years; 20 patients (48.8%) had node-positive disease. RS was 0-10 in nine patients (22.0%), 11-25 in 25 (61.0%), and ≥26 in 7 (17.1%). Treatment recommendations changed in 16 patients (39.0%): chemotherapy was omitted in 13 (31.7%) and added in 3 (7.3%). Among 34 patients with RS ≤25, 29 (85.3%) received endocrine therapy alone and 5 (14.7%) received chemo-endocrine therapy. Patients receiving chemotherapy were younger (median 48 vs. 59 years, p=0.049) and had higher RS values (median 17 vs. 13, p=0.007). Among 20 node-positive patients, 15 (75.0%) received endocrine therapy alone.

Conclusion: RS testing altered adjuvant treatment recommendations in 39.0% of patients, predominantly through chemotherapy omission. In patients with RS ≤25, younger age and higher RS were associated with chemotherapy use, suggesting that genomic and clinicopathological information were integrated in routine decision-making.

Related

  1. Real-World Treatment Utilization and Patterns of Adjuvant Olaparib for Early-Stage Breast Cancer: Insights from the Komodo Research Database.
    Felipe Batalini, Qixin Li, Jennifer F Hayes +5
    Current oncology (Toronto, Ont.)Peer-reviewedCC BYFull textOncologyEurope PMC
  2. Distinct sleep and rest-activity profiles according to adjuvant treatment exposure in women treated for breast cancer
    Alicia Leclercq, Abderrahmane Rahmani, Baptiste Morel +13
    The OncologistPeer-reviewedCC BY-NCEcologyEpidemiology & public healthHAL
  3. Case Report: Ribociclib-associated bilateral neurotrophic keratitis requiring amniotic membrane transplantation during adjuvant treatment of early breast cancer
    Danielle DeCicco, Sanjana Nethagani, Lingo Lai +1
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  4. Impact of neoadjuvant chemotherapy on local breast microbiota and macrophages in ER-positive breast cancer with links to treatment response
    Sabine Dieleman, Carlijn Bruggeling, Phuc Dat Le +14
    NPJ Breast CancerPeer-reviewedCC BY 4.0Full text1 citedOncologyPMC
  5. Recurrence patterns and adjuvant therapy in endometrioid early-stage endometrial cancer with a p53-abnormal pattern
    S. h. Lee, P. D. Karimah, K. KIM +6
    medRxivPreprintCC BY-NCFull textObstetrics, gynaecology & paediatricsmedRxiv

Cite

BibTeXRIS
BibTeX
@article{kittaka2026realworld,
  title = {{Real-world Impact of the 21-Gene Recurrence Score on Adjuvant Treatment Decisions in Early Breast Cancer}},
  author = {NOBUYOSHI KITTAKA and NAMIKO TANAKA and CHISATO TAKEUCHI and KANA ANNO},
  journal = {In Vivo},
  year = {2026},
  month = oct,
  doi = {10.21873/invivo.14506},
  url = {https://doi.org/10.21873/invivo.14506},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Real-world Impact of the 21-Gene Recurrence Score on Adjuvant Treatment Decisions in Early Breast Cancer
AU  - NOBUYOSHI KITTAKA
AU  - NAMIKO TANAKA
AU  - CHISATO TAKEUCHI
AU  - KANA ANNO
PY  - 2026
DA  - 2026/10/29
JO  - In Vivo
DO  - 10.21873/invivo.14506
UR  - https://doi.org/10.21873/invivo.14506
AB  - Background/Aim: The 21-gene recurrence score (RS) assay guides adjuvant chemotherapy decisions in hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer. We evaluated how RS results altered treatment recommendations and were integrated with clinicopathological factors in routine practice.  Patients and Methods: We retrospectively analyzed 41 consecutive patients who underwent RS testing for postoperative treatment planning at a single institution. Pre-test and post-test treatment recommendations were compared. Exploratory analyses examined patients with RS ≤25 who received chemotherapy and treatment patterns in node-positive disease.  Results: Median age was 58 years; 20 patients (48.8%) had node-positive disease. RS was 0-10 in nine patients (22.0%), 11-25 in 25 (61.0%), and ≥26 in 7 (17.1%). Treatment recommendations changed in 16 patients (39.0%): chemotherapy was omitted in 13 (31.7%) and added in 3 (7.3%). Among 34 patients with RS ≤25, 29 (85.3%) received endocrine therapy alone and 5 (14.7%) received chemo-endocrine therapy. Patients receiving chemotherapy were younger (median 48 vs. 59 years, p=0.049) and had higher RS values (median 17 vs. 13, p=0.007). Among 20 node-positive patients, 15 (75.0%) received endocrine therapy alone.  Conclusion: RS testing altered adjuvant treatment recommendations in 39.0% of patients, predominantly through chemotherapy omission. In patients with RS ≤25, younger age and higher RS were associated with chemotherapy use, suggesting that genomic and clinicopathological information were integrated in routine decision-making.
SN  - 0258-851X
SN  - 1791-7549
ER  -